Pharmacological use of gamma-aminobutyric acid derivatives in osteoarthritis pain management: a systematic review.

Abstract

BACKGROUND:

Pain is the major complication of osteoarthritis (OA) patients and is a decisive symptom for medical intervention. Gamma-aminobutyric acid (GABA) derivatives are optional painkillers but not widely used in pain management of OA patients. We synthesized the efficacy and safety of GABA derivatives for OA pain management.

METHODS:

We searched Medline, Cochrane CENTRAL, Embase, and ClinicalTrals.gov from inception to 13 October 2021 and included randomized controlled trials (RCTs) comparing the efficacy and safety of GABA derivatives with placebo or standard control in OA pain management. Two independent reviewers extracted data and assessed these studies for risk of bias using Cochrane Collaboration's tool for RCT.

RESULTS:

In total, three eligible RCTs (n = 3) meeting the eligibility criteria were included. Among these RCTs, one focused on hand OA pain management, while two RCTs focused on knee OA. In hand OA, pregabalin reduced numerical rating scale (NRS) score and the Australian/Canadian Osteoarthritis Hand Index (AUSCAN) pain score significantly compared with placebo, and caused 55 AEs. In knee OA, pregabalin reduced visual analogue scale (VAS) score and the Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain score significantly with no recorded adverse event (AE). Meanwhile, in knee OA, gabapentin reduced both VAS score and WOMAC pain score compared with acetaminophen and caused 9 AEs.

CONCLUSIONS:

GABA derivatives seem to be effective and safe in OA pain management. However, future researches with large sample size are needed to further prove the efficacy of GABA derivatives in OA pain control.

TRIAL REGISTRATION:

CRD42021240225.

• Authors: Ze Du, Hanxiao Chen, Yongrui Cai, Zongke Zhou
• Journal: BMC rheumatology (BMC Rheumatol) Vol. 6 Issue 1 Pg. 28 (May 11 2022) ISSN: 2520-1026 [Electronic] England
• PMID: 35538592 (Publication Type: Journal Article)
• Copyright: © 2022. The Author(s).